Lipid Profile Improved after Alirocumab Treatment for Lorlatinib Associated Dyslipidemia: A Case Report

Jui-Hsiang Sung ； Fang-Yu Chen ； Tsung-Hui Wu ； Hui-Ling Lin ； Tang-Yi Liao ； Chii-Min Hwu

《Formosan Journal of Endocrinology and Metabolism》 預刊文章 Pp. 66-71

https://doi.org/10.6856/FJEM.202406/PP_16(1).0011

摘要

Lorlatinib, a highly potent third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), is employed in the treatment of ALK-positive metastatic non-small cell lung cancer. Despite commonly observed adverse events such as hyperlipidemia, central nervous system (CNS) effects, body weight increase, edema, and peripheral neuropathy, lorlatinib is generally well tolerated. This case study highlights lorlatinib-induced dyslipidemia initially managed with a combination of high-intensity statin and ezetimibe, yielding suboptimal results. However, the lipid profile exhibited gradual improvement following the addition of alirocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.

關鍵字

lorlatinib ； alirocumab ； hyperlipidemia ； PCSK9 inhibitor